Chiesi Spain organizes in Madrid a meeting on the importance of small airway

Madrid, November of 2011. On 2 November was a meeting in Madrid with the title the importance of small airway ”. The event held in the building of the Bolsa de Madrid was sponsored by Chiesi Spain and it counted with the participation of around 150 specialists in the area of Pneumology and Allergology of Madrid, Guadalajara, Toledo, Ciudad Real and Valladolid.

In recent years has been revived interest in the study of the role of airway small in the pathophysiology and treatment of obstructive bronchial diseases.

The introduction of methods not invasive as the measurement of nitric oxide and other indicators parameters of inflammation in the exhaled air, the histological study of transbronquiales biopsies and the emergence of new techniques for diagnostic imagingthey have revived the interest by the inflammatory process that affects the small Airways.

The fact that this area is difficult to access for drugs via inhalation has stimulated the search for drugs, administered by systemic way or new systems of inhalation which they manage to produce extra-thin particles, they facilitate his arrival in the small Airways contributing to improve the therapeutic results obtained with anti-inflammatory drugs.

This meeting was an update on what is known about the anatomy, Physiology and pathology of small Airways and also showed examples of imaging techniques to assess the involvement in these pathwaystherapeutic modalities that are today available to doctors, to facilitate the arrival of anti-inflammatory drugs in the distal portion swollen, either via systemic or inhaled were finally revised.

The scientific programme featured two excellent moderators, DRA. Pillar of Lucas, elected President of SEPAR and Dr. Tomás Chivato, former President of the SEAIC, and 4 speakers renowned in small airway such as the Dr. Francisco García River, Dr. Julio Delgado, Dr. Germán Peces-Barba and Dr. Tomás Franquet.

Chiesi Farmaceutici

CHIESI Farmaceutici is a multinational pharmaceutical headquartered in Parma (Italy) founded 75 years ago.

In recent years has decided to concentrate maximum efforts of r & d ­­­­­­­­­­­­­­­­­­­­­­­­en the respiratory area, where your knowledge is very broad, to devote 15 per cent of its sales revenues to research such targeting in this therapeutic area has given their first fruits with launches of new drugs inhaled under the Modulite ® technology platform.

CHIESI has an extensive portfolio of innovative products and more than 360 registered patents. The Group has four research centers, in Parma (Italy), Paris (France), Rockville (United States), and finally in Chippenham (United Kingdom) with more than 300 researchers and currently are being developed, in different phases of pre-clinical and clinical, 23 new drugs. Likewise, CHIESI has signed agreements with universities in various countries.